This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
XRAY or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. CNMD: Which Stock Is the Better Value Option?
Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?
by Zacks Equity Research
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
10 Top-Ranked S&P 500 Stocks Outperforming in 2020
by Sweta Killa
The rally has been broad based and there are winners across various corners of the space.
Masimo Posts Solid Preliminary 2019 Results, Issues Guidance
by Zacks Equity Research
Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.
Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.
Here's Why You Should Hold on to Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and growth in worldwide da Vinci procedure volume benefit Intuitive Surgical's (ISRG) preliminary Q4 results.
Veeva Systems Boosts Product Portfolio With New Application
by Zacks Equity Research
Veeva Systems (VEEV) introduces Veeva Vault Payments, which is likely to bolster the company's already robust product portfolio.
Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
XRAY or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. ALGN: Which Stock Is the Better Value Option?
Why Is Dentsply (XRAY) Up 1.7% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Orthodontic Stocks to Keep an Eye On
by Sriparna Ghosal
Growth in the orthodontics market has been primarily led by rising focus of vendors on emerging markets, such as Asia-Pacific and LAMEA.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises 2019 revenue and EPS guidance.